BAYRY Stock Recent News

WHIPPANY, N.J.--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant. "We are successfully delivering on our ambitious business goals despite significant headwinds. At the same time, the value of our pipeline is growing by accelerating breakthrough innovations,”.

Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Copper Ammonium Carbonate Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The copper ammonium carbonate market is expected to grow at a CAGR of 6.69%, reaching a market size of US$13.209 billion in 2030 from US$9.557 billion in 2025. The copper ammonium carbonate market is characterized by its wide application as a fungicide in the agri-business, especially for crops but not limited to wheat, barley, and oats. This compound plays an important part in boosting the yield and quality of crops, which is a major concern considering the rise in food demand from a highly populated world. The advantages associated with this compound have also caused its demand in certain industries. However, there is competition for the market from the green alternatives and a change in perception towards chemical fungicides in turn which will leave the farmers with no options but to evolve to organic farming pract

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on Tuesday.

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). All QUANTI studies investigated gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone) for the treatment of patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%. The submission is based on positive results from the Phase III FINEARTS-HF trial that showed finerenone achieved a statistically significant reduction of the composite of cardiovascular death and t.

ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET          Orion's collaboration partner Bayer submits application in China for third indication of darolutamide Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

LEVERKUSEN, Germany--(BUSINESS WIRE)--The Federal Court of Australia brought an end to the last Roundup™ case in Australia, closing all pending injury litigation there. The Court granted the plaintiffs' request to discontinue the Fenton class action against Monsanto involving allegations related to Roundup™. This action follows the company's earlier victory in the McNickle case in the same court. McNickle was the first Roundup™ final judgment outside of the United States on the question of whet.

BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.

MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). “Simply put, our ambition is to help more patients with prostate cancer,” said Christine Roth, Executive Vice President, G.